A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors

Trial Profile

A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Anal cancer; Bladder cancer; Breast cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Pancreatic cancer; Renal cancer; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 24 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top